health


Poda Receives Final Approval from OTC Markets to List on the QTCQB

January 10th, 2022 - Ryan Allway

VANCOUVER, BC , Jan. 10, 2022 /CNW/ – PODA HOLDINGS, INC. (“Poda” or the “Company”) (CSE: PODA) (FSE: 99L) (OTC: PODAF) is pleased to announce the Company has received official notification from OTC Markets to up-list from Pink Sheet to the OTCQB tier effective as of January 6, 2022 . The OTCQB is a US trading platform that is operated by the OTC […]

BioHarvest Looks to Make Cannabis More Sustainable

October 13th, 2021 - Ryan Allway

Investors have become increasingly environmentally conscious over the past few years, evidenced by the tremendous growth in ESG funds. But, unfortunately, investors in the cannabis industry may be surprised by its significant environmental impact. Fortunately, many companies are working to improve the situation and make the industry more “green.” Let’s take a closer look at […]

Big Pharma Dives Into CBD: Who Could Be Next?

February 22nd, 2021 - Robin Lefferts

As many of you know, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) agreed in early February to acquire GW Pharmaceuticals plc (NASDAQ: GWPH) for a total price tag, including cash and shares, of $7.2 billion. GW Pharma is a pioneer in cannabinoid-based medicine, and its cannabidiol (CBD) formulation Epidiolex® is notably the first plant-derived cannabinoid medicine ever […]

Psychedelic Clinical Trials & Who’s Behind Them

February 18th, 2021 - Ryan Allway

The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon. […]

Psychedelics: Significant Investor Interest Despite the Pandemic

February 16th, 2021 - Ryan Allway

  The COVID-19 pandemic may be ravaging large swaths of the economy, but the stock market has consistently hit new record highs. After spending several years under-the-radar, the psychedelics industry is experiencing a renaissance driven by a combination of FDA-driven catalysts and soaring investor interest in a new class of potential blockbuster therapeutics.  Let’s take […]

Delic Looks to Build a Sprawling ‘Psychedelic Ecosystem’

January 20th, 2021 - Ryan Allway

There have been a number of high profile initial public offerings in the psychedelic space, including COMPASS Pathways’ (NASDAQ: CMPS) $2 billion debut. While there are now more than 30 publicly traded companies in the space, there are thousands more private companies at various stages of funding and development.  Delic Corp. (CSE: DELC) (OTCQB: DELCF) […]

CBD Innovator, HempFusion, Makes Successful Debut on TSX

January 13th, 2021 - Ryan Allway

  HempFusion Wellness Inc. (TSX: CBD-U) shares soared over 65% following their successful debut on the Toronto Stock Exchange (TSX) on Wednesday, January 6, 2021. Cannabidiol, or CBD, has become one of the most popular health and wellness products in the world over the past couple of years. According to Research and Markets, the global […]

Pure Extracts Unveils Plans for Functional Mushrooms

November 30th, 2020 - Ryan Allway

  There are more than 2,000 species of edible fungi and at least 15 have functional benefits that support overall health. Like other superfoods, functional mushrooms have antioxidant properties that support the immune system, dietary fiber to aid in healthy digestion and numerous other benefits to everything from mental clarity to skin health. At the […]

CBD Makes Its Way into Mainstream Retail

November 19th, 2020 - Ryan Allway

The U.S. market for CBD products is projected to reach $23.7 billion by 2023, according to Brightfield Group, representing a seven-fold increase in the market’s size. While it’s one of the fastest-growing subsets of the multi-trillion-dollar wellness industry, CBD products remain absent from most mass-market retailers. CVS became the first large-scale retailer to offer CBD […]

Cardiol Therarpeutics Receives FDA Approval For Investigational New Drug (IND) Application For Phase II/III COVID-19 Trial

September 25th, 2020 - Ryan Allway

Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) Oakville, Ontario–(Newsfile Corp. – September 25, 2020) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company“), a clinical-stage biotechnology company focused […]

3 Beverage Mega-Trends that Investors Should Watch

June 15th, 2020 - Ryan Allway

Beverages play a key role in almost everyone’s life—from coffee in the morning to an alcoholic drink at dinner or with friends. While the same large companies have dominated the space for years, smaller innovators have experienced the fastest growth rates as they launch high-growth products before getting snapped up by larger competitors. The key […]

THC BioMed Reports Growing Revenue & Profitability

April 22nd, 2020 - Ryan Allway

Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations. THC BioMed Intl Ltd. (CSE: THC) recently recorded its […]

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

April 6th, 2020 - Ryan Allway

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]

Science-driven Brand Delivers 5 Perfected Cannabis Highs

April 6th, 2020 - Robin Lefferts

What happens when the investment environment surrounding cannabis companies evaporates amid concerns about overvaluations and lack of returns? And then, a worldwide pandemic reverses years of economic growth almost overnight, plunging economies into near-instant depression? One thing that happens is some quality companies become distressed, offering investors the opportunity to purchase a stake at a […]

Coping With Stress During the COVID-19 Outbreak with CBD & Adaptogens

April 2nd, 2020 - Ryan Allway

The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other side-effects. It’s important for everyone to take inventory of their health and […]

Israel Begins Cannabis Exports to Meet Unmet Medical Needs

March 30th, 2020 - Ryan Allway

Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s […]

5 Ways to Participate in the Psychedelics Boom

March 27th, 2020 - Ryan Allway

The psychedelics industry is quickly becoming the next frontier market for investors as the cannabis industry matures. Through a combination of cutting-edge research and decriminalization, investors are hoping that the industry moves in the same direction as medical cannabis over the coming years. Let’s take a look at five public companies in the space and […]

Isracann Enters JV for Near-Term Cannabis Farm Production Opportunity in Israel

March 24th, 2020 - Ryan Allway

24 MAR 2020 / CORPORATE NEWS Partnership advances time-to-market to under six months VANCOUVER, BC, — (March 24, 2020) – Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is […]

Adaptogens, Functional Beverages, and CBD

March 16th, 2020 - Ryan Allway

It’s a stressful world out there, and consumers know it. In growing numbers, people are looking for healthy foods, naturally sourced, to keep both themselves and the planet on a positive track. If those foods can also relieve stress and help people relax, all the better. Beverages are a prime example of the trend toward […]

Psychedelics, the Next Frontier in Drug Research

March 1st, 2020 - Ryan Allway

A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin to insulin to penicillin. A decent body of research is currently pointing to psilocybin, the psychedelic […]

The Future of Cannabis Retail Is Here

February 12th, 2020 - Robin Lefferts

Cannabis has been grown and sold illicitly for generations in California. But legal sales of cannabis through retail stores is still relatively new. With black- and gray-market sellers as precursors, most cannabis dispensaries today don’t stray far from the old-school medical dispensary or head-shop model – cramped and crammed with a wide variety of products […]

Supreme Cannabis Focuses Organization and Reduces Cost Structure to Accelerate Profitable Growth

February 11th, 2020 - Ryan Allway

Corporate positions decreased by approximately 33% and operational positions decreased by approximately 13% Total number of positions decreased by approximately 15% across the Company New structure focuses the business on accelerating revenue growth in the Canadian market TORONTO, February 11, 2020 – The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: […]

Supreme Cannabis 2020, A Simple Approach On The Path To Profitability

January 23rd, 2020 - Ryan Allway

Many expect 2020 to go down as the shakeout year for the Canadian cannabis industry; the year where winners will make their way to the top and companies with weak fundamentals will be ruled out. Of the potential winners, The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) is one Canadian player that stands out with its […]

Supreme Cannabis Announces Leadership Transition as Company Accelerates Transformation into Premium Cannabis CPG Company

January 6th, 2020 - Ryan Allway

Supreme Cannabis Board Director and former President of Starbucks Coffee Canada, Colin Moore, appointed Interim President and CEO. Navdeep Dhaliwal departs Company, effective immediately. Interim CEO to leverage successful track record to accelerate growth and transformation strategy, while improving speed to market and rightsizing operating and capital spends. Search for new CEO to begin immediately. […]

Investors Opening Eyes to Opportunity in Israel Cannabis, Including Exclusive CEO Video Interview Part #2

December 23rd, 2019 - Ryan Allway

There is no country on Earth that has a history steeped in cannabis research like that of Israel. Furthermore, there is no government that is more supportive of medical marijuana research than Israel. Yet, the small country has by and large gone overlooked for what it has to offer as an investment opportunity. That is […]

Canadian Cannabis Success Being Replayed in Israel Right Now, Featuring an Exclusive Isracann Biosciences CEO Video Interview Part #1

December 18th, 2019 - Ryan Allway

After experiencing success with the legalization of cannabis in Canada, Darryl Jones was looking for the next big cannabis opportunity. As it happens, that opportunity was 11,000 miles away from Vancouver in Israel. Fast forward and Jones is now President and CEO of Isracann Biosciences (CSE: IPOT) (OTCPK: ISCNF), Israel’s first pure-play cannabis company to […]

Isracann Closer to Greenhouse Construction as Israel Cannabis Market Heats Up

December 10th, 2019 - Ash Stringer

Israel has long been recognized for its pioneering contributions to research in the medical cannabis field. Recently, the state made its commitment clear to develop the sector by issuing a white paper on the opportunity to invest in Israeli cannabis. That was followed by the largest medical-marijuana merger ever in the country, with Cannbit Pharmaceuticals […]

Canibrands Capitalizes on CBD with Deep Product Line & Celebrity Support

December 6th, 2019 - Ryan Allway
CaniBrands products

Cannabidiol, better known as CBD, has become one of the most popular wellness products in the United States over the past couple of years. BDS Analytics and Arcview Market Research expect CBD sales to grow at a 49% compound annual growth rate to surpass $20 billion by 2024—making up about half of the total cannabinoid […]

Israel Writing Playbook to Become Cannabis Gateway to Europe

November 21st, 2019 - Ash Stringer

With unprecedented expertise in cannabis research and perfect weather conditions for cultivation, it only makes sense that Israeli lawmakers took a global leadership position in January 2019 by green-lighting the export of medical cannabis to countries where it is allowed. Then it just became a matter of establishing the framework to become one of only […]

Strength in Numbers: The Name You Don’t Know in Cannabis, But Should…GreenStar Biosciences

November 20th, 2019 - Ash Stringer

Centene. Energy Transfer. Tech Data. Arrow Electronics. What do these companies have in common? They each generate over $40 billion a year in revenue and most people have never heard of any of them. Investors that have enjoyed triple-digit returns from all of them over the last decade probably don’t mind too much that the […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading